| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Cancer Center (YC, S-HY, W-KC), Division of Gastroenterology (C-PL, C-PC, F-YC, S-DL), Department of Medicine, and Division of General Surgery (G-YC, K-LK, W-YL), Department of Surgery, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Correspondence: Address correspondence and reprint requests to: Yee Chao, MD, PhD, Cancer Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 112, Taiwan; Fax: 88-62-28-74-9425; E-mail: ychao{at}vghtpe.gov.tw
Background: Hepatocellular carcinoma (HCC) is a hypervascular malignancy. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiogenin (ANG) are important angiogenic factors of neoangiogenesis. This study investigated the predictive value of serum VEGF, bFGF, and ANG in tumor recurrence, disease-free survival (DFS), and overall survival (OS) in HCC patients.
Methods: Preoperative serum VEGF, bFGF, and ANG were measured in 98 patients with resectable HCC and in 15 healthy controls. The median follow-up time was 43 months.
Results: Preoperative serum VEGF was increased in patients with resectable HCC compared with healthy controls (P < .05). Increased serum VEGF was correlated with tumor recurrence (P = .001). Univariate analysis showed that serum VEGF, tumor-node-metastasis stage, tumor size and number, macroscopic portal vein invasion, and microscopic vascular invasion were correlated with OS and DFS. Serum bFGF and ANG were not associated with survival. Multivariate analysis showed that serum VEGF was the most significant predictor of DFS (relative risk, 2.35; 95% confidence interval, 1.26–4.39; P = .007) and OS (relative risk, 3.44; 95% confidence interval, 1.81–6.57; P < .001) in HCC patients after surgical resection.
Conclusions: Preoperative serum VEGF is a significant independent predictor of tumor recurrence, DFS, and OS in patients with resectable HCC.
Key Words: Angiogenin • Basic fibroblast growth factor • Hepatocellular carcinoma • Vascular endothelial growth factor
This article has been cited by other articles:
 |
|
 |
|
  M. B. Thomas, J. S. Morris, R. Chadha, M. Iwasaki, H. Kaur, E. Lin, A. Kaseb, K. Glover, M. Davila, and J. Abbruzzese Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma J. Clin. Oncol., February 20, 2009; 27(6): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu, N. S. Holalkere, A. Muzikansky, K. Horgan, and D. V. Sahani Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma Oncologist, February 1, 2008; 13(2): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. P. Poon, C. Lau, R. Pang, K. K. Ng, J. Yuen, and S. T. Fan High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies Ann. Surg. Oncol., June 1, 2007; 14(6): 1835 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? Oncologist, July 1, 2006; 11(7): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, A. Muzikansky, K. Horgan, S. Sheehan, K. E. Hale, P. C. Enzinger, P. Bhargava, et al. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma J. Clin. Oncol., April 20, 2006; 24(12): 1898 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, C. S. Fuchs, J. W. Clark, A. Muzikansky, K. Taylor, S. Sheehan, K. Tam, E. Yung, M. H. Kulke, and D. P. Ryan A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma Oncologist, June 1, 2005; 10(6): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Pandharipande, G. A. Krinsky, H. Rusinek, and V. S. Lee Perfusion Imaging of the Liver: Current Challenges and Future Goals Radiology, March 1, 2005; 234(3): 661 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Claudio, G. Russo, C. A. C. Y. Kumar, C. Minimo, A. Farina, S. Tutton, G. Nuzzo, F. Giuliante, G. Angeloni, V. Maria, et al. pRb2/p130, Vascular Endothelial Growth Factor, p27(KIP1), and Proliferating Cell Nuclear Antigen Expression in Hepatocellular Carcinoma: Their Clinical Significance Clin. Cancer Res., May 15, 2004; 10(10): 3509 - 3517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-N. Vauthey and J. A. Ajani Liver Transplantation and Hepatocellular Carcinoma Biology: Beginning of the End of the Era of Educated Guesses J. Clin. Oncol., December 1, 2003; 21(23): 4265 - 4267. [Full Text] [PDF]
|
|
|
|
|
|
S. Ferrero and N. Ragni Prognostic Value of Plasma and Serum VEGF Levels in Patients With Resectable Hepatocellular Carcinoma Ann. Surg. Oncol., November 1, 2003; 10(9): 1123 - 1123. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
